BUZZ2.750%
as of Jul 17
IBRX
DefensiveImmunityBio, Inc.
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors.
Close · 3M
-11.30%
Held by 1 AI ETF
Signal performance
Each tracked ETF's moves on this stock, grouped by fund. Returns are measured from the signal date to the latest close — hypothetical, no commissions or slippage.
Buy signals17
Win rate47% (8/17)
Avg buy return-3.14%
BUZZ · Weight decrease · 2d
The weight for ImmunityBio, Inc. in BUZZ first showed a gradual decline from 3.78% to 3.38% between July 7th and July 15th, then a more significant reduction to 2.62% on July 16th. This extended sequence of decreasing allocation reflects a cooling of positive sentiment intensity detected by BUZZ’s NLP engine. Given ImmunityBio's 1-year return of 182.4% but a recent 90-day decrease of 4.1%, the previous surge in social media and news discussions that likely drove its high weighting is diminishing. BUZZ, which passively ranks US large/mid caps by positive-sentiment intensity, thus adjusts its holdings as the retail-crowd signal for IBRX softens from its prior peak when the stock was trading closer to its $11.55 high. This specific reduction follows the pattern of the algorithmic sentiment tracker reducing exposure to a stock after a period of significant price appreciation followed by some retracement.
weight 3.420% → 2.620% (-0.800 pp)·stock up 4.5% in the 30 days before
Jul 16·entry $7.45·now $7.50
+0.60%
since Jul 16
BUZZ · Weight decrease · 3d
VanEck's BUZZ ETF, which tracks sentiment leaders through NLP analysis of social media and news, registered a consecutive weight decrease for ImmunityBio, Inc. (IBRX). The observed reduction from 3.75% to 3.40% across several trading days in July indicates a weakening positive sentiment intensity detected by the fund's algorithmic tracker. This shift suggests a diminished "retail-crowd signal" for IBRX among the ~75 US large/mid caps the ETF holds, likely positioning the stock for reduced allocation during the monthly index reconstitution. Such a change in sentiment occurs as IBRX trades at $7.88, despite having recorded a 90-day return of -12.1%.
weight 3.780% → 3.400% (-0.380 pp)·stock up 11.6% in the 30 days before
Jul 13·entry $7.79·now $7.50
-3.79%
since Jul 13
BUZZ · Weight decrease · 2d
VanEck's BUZZ fund, which tracks an index by ranking stocks based on positive-sentiment intensity derived from NLP analysis of social media and news, registered a shift regarding ImmunityBio, Inc. (IBRX). The observed consecutive decline in IBRX's weight on July 9th and 10th, dropping from 3.7500% to 3.5100%, indicates a softening in the collective online sentiment for the company, prompting this reduction within the fund's ~75 holdings. This algorithmic adjustment suggests the NLP model picked up a cooling of enthusiasm for IBRX, perhaps influenced by the stock's 90-day return showing a 13.4% decline, despite a positive 3.6% gain over the last 30 days. As an algorithmic sentiment tracker, BUZZ passively rebalances its portfolio based on such evolving sentiment signals rather than active fundamental analysis, positioning it as a direct reflection of broader retail-crowd interest.
weight 3.780% → 3.510% (-0.270 pp)·stock up 13.4% in the 30 days before
Jul 10·entry $8.22·now $7.50
-8.82%
since Jul 10
BUZZ · Accumulation · 5d
The BUZZ ETF demonstrated a gradual accumulation of ImmunityBio (IBRX), increasing its weight from 3.0900% to 4.0000% between late June and early July 2026. This steady progression reflects a building positive sentiment intensity detected by BUZZ’s NLP engine across social media and news, coinciding with IBRX’s recent +15.1% 30-day return. With IBRX trading at $8.91, approximately 77% of its 52-week high, the stock presents a discernible, not extreme, level of engagement from the retail crowd whose collective signals BUZZ tracks. Such a pattern is characteristic of BUZZ's algorithmic sentiment tracker, which passively holds stocks based on evolving public discourse rather than executing rapid, discretionary trades, even with its monthly index reconstitution.
weight 3.090% → 4.000% (+0.910 pp)·stock up 30.6% in the 30 days before
Jul 2·entry $9.44·now $7.50Fresh
-20.60%
since Jul 2
BUZZ · Accumulation · 5d
ImmunityBio (IBRX) is currently priced at $9.44, sitting at 82% of its 52-week high of $11.55, following a recent 30-day gain of 17.3% that recovered some ground from a 90-day decline of 18.3%, all while maintaining a 1-year return of 228.9%. Against this backdrop, the BUZZ ETF, which passively tracks a sentiment index derived from NLP analysis of social media and news, detected a gradual increase in positive sentiment surrounding the Health Care company. This sustained positive sentiment, likely reflecting the retail-crowd's interest as the stock rebounded from its quarterly dip while still far above its yearly low, directly influenced the index's ranking of IBRX. Consequently, during its monthly index reconstitution, BUZZ slowly increased its allocation to IBRX from 2.97% to 3.85% between late June and early July, a measured response typical of its algorithmic sentiment tracker methodology rather than an active AI management decision.
weight 2.970% → 3.850% (+0.880 pp)·stock up 27.1% in the 30 days before
Jul 1·entry $9.20·now $7.50Fresh
-18.53%
since Jul 1
BUZZ · Weight decrease · 2d
ImmunityBio, Inc. (IBRX) currently trades at $9.20, positioning it at 80% of its 52-week high of $11.55, after recording a 30-day return of +18.6% and a 90-day return of -6.4%. This volatile price action interacts directly with the BUZZ ETF's methodology, which tracks the BUZZ NextGen AI US Sentiment Leaders Index by analyzing positive-sentiment intensity from social media, blogs, news, and message boards. The consecutive weight decrease detected for IBRX within BUZZ, specifically from 3.77% on June 26th down to 3.65% by June 30th, with drops on June 29th and June 30th, signals a cooling in the positive-sentiment intensity captured by the ETF's NLP algorithms. This movement reflects a shift in the collective online discussion for a stock that has seen substantial year-over-year growth, aligning with BUZZ’s function as an algorithmic sentiment tracker sensitive to retail crowd signals. The ETF's passive holding, rebalancing monthly, therefore reflects a real-time dip in perceived enthusiasm following a period of price fluctuation around its 52-week high.
weight 3.770% → 3.650% (-0.120 pp)·stock up 16.4% in the 30 days before
Jun 30·entry $8.76·now $7.50
-14.39%
since Jun 30
BUZZ · Accumulation · 5d
ImmunityBio, Inc. is currently trading at $8.76, reflecting a +9.4% return over the past 30 days and a +208.3% gain over the last year, positioning it at 76% of its 52-week high of $11.55. This recent upward movement, combined with its longer-term performance, likely generated a sustained positive sentiment among the retail crowd, which BUZZ's algorithmic tracker directly captures. The fund, known for its NLP-driven analysis of social media and news to track sentiment intensity, registered a growing positive discussion for IBRX during this period. This continuous signal prompted a gradual accumulation of the stock, leading to its weight in BUZZ increasing from 2.6000% to 3.7000% between June 17 and June 29, 2026. This demonstrates how a stock with consistent positive momentum, even when off its absolute peak, can rise in prominence within a sentiment-based portfolio designed to reflect retail signals.
weight 2.600% → 3.700% (+1.100 pp)·stock up 13.6% in the 30 days before
Jun 29·entry $8.77·now $7.50Fresh
-14.54%
since Jun 29
BUZZ · Accumulation · 6d
VanEck's BUZZ ETF, which tracks the sentiment of approximately 75 US large/mid caps by processing social media, blogs, and news with NLP, has shown a clear pattern of gradual accumulation in ImmunityBio (IBRX). This persistent increase in weight, climbing from 2.48% to 3.77% over a ten-day period, indicates a sustained and growing positive sentiment detected by the fund’s algorithmic methodology, aligning with its monthly index rebalancing schedule. Such a prolonged positive shift in public discourse often follows significant price movements, like IBRX's 1-year return of +180.2%, which likely amplified its presence across discussion platforms. The fund's reliance on crowd-sourced signals, captured through its NLP engine, positions it to respond to the very trends of retail discussion that would elevate a company like IBRX after such considerable performance.
weight 2.480% → 3.770% (+1.290 pp)·stock up 10.4% in the 30 days before
Jun 26·entry $8.71·now $7.50Fresh
-13.95%
since Jun 26
BUZZ · Accumulation · 5d
ImmunityBio (IBRX) is currently priced at $8.71, sitting at 75% of its 52-week high after a 183.7% one-year return, alongside 30-day and 90-day returns of +6.9% and +2.0% respectively. This sustained positive momentum in a stock that has already seen considerable long-term appreciation aligns directly with the BUZZ ETF's algorithmic approach, which identifies and ranks stocks based on accumulating positive sentiment from social media and news. The observed gradual accumulation, increasing IBRX's weight from 2.57% to 3.41% over a ten-day span in late June, reflects a consistent strengthening of this positive retail-crowd signal detected by the fund's NLP models. This suggests IBRX's ongoing favorable perception within the US large/mid-cap retail discussion landscape, leading to its higher allocation within the passively managed index as sentiment intensified.
weight 2.570% → 3.410% (+0.840 pp)·stock down 1.6% in the 30 days before
Jun 25·entry $7.79·now $7.50Fresh
-3.79%
since Jun 25
BUZZ · Weight increase · 2d
IBRX currently trades at $7.79, reflecting a +144.2% 1-year return and a +29.4% 90-day return, although its 30-day performance shows a -4.4% dip; the stock sits at 67% of its $11.55 52-week high. This setup, with the stock having cooled from its high but maintaining strong longer-term gains, appears to have coincided with increasing positive sentiment detected by the VanEck BUZZ ETF, which tracks social media, blogs, and news for sentiment intensity. The detected pattern of consecutive weight increases in BUZZ, specifically from 2.48% on June 16th to 3.36% by June 24th, indicates a growing intensity of positive retail-crowd signals around IBRX. Such a sustained climb in allocation points to the fund’s algorithmic process identifying a significant and broadening bullish consensus among the market participants it monitors, rather than an active management decision.
weight 2.970% → 3.360% (+0.390 pp)·stock up 8.0% in the 30 days before
Jun 24·entry $7.80·now $7.50Fresh
-3.91%
since Jun 24
BUZZ · Weight increase · 2d
ImmunityBio (IBRX) trades at $7.22, 63% of its 52-week high, following a 30-day return of -15.2% against a 1-year gain of +109.9%. After its weight in BUZZ declined to 2.48% by June 16th, the ETF made consecutive increases to 2.60% and then 2.98% on June 17th and 18th. This rapid re-weighting reflects a shift detected by VanEck's NLP algorithm, which monitors social media and news for positive sentiment intensity. The algorithmic sentiment tracker, closely tied to retail-crowd signals, likely observed renewed positive discourse around IBRX at this valuation, prompting its increased ranking within the portfolio during the monthly index reconstitution period.
weight 2.480% → 2.980% (+0.500 pp)·stock down 5.2% in the 30 days before
Jun 18·entry $7.36·now $7.50Fresh
+1.83%
since Jun 18
BUZZ · Weight decrease · 5d
ImmunityBio, Inc. (IBRX) has experienced a 30-day return of -16.6%, with its current price of $6.99 sitting at 61% of its 52-week high of $11.55. The VanEck BUZZ fund, which operates as an algorithmic sentiment tracker monitoring retail-crowd signals from social media and news, responds directly to shifts in positive-sentiment intensity. A pattern of consecutive weight decreases for IBRX in BUZZ, observed from June 10th at 2.71% down to 2.48% by June 16th, closely followed this recent price weakness. This specific reduction in allocation reflects a measurable decline in positive sentiment gathered by the fund’s NLP-driven index as the stock's momentum faltered, triggering adjustments during its monthly reconstitution.
weight 2.720% → 2.480% (-0.240 pp)·stock down 15.7% in the 30 days before
Jun 16·entry $6.72·now $7.50
+11.53%
since Jun 16
BUZZ · Weight decrease · 4d
IBRX currently trades at $6.72, which places it at 58% of its 52-week high, following a recent 30-day return of -11.3% despite a 1-year return of +129.4%. This recent short-term downturn, occurring after substantial longer-term gains, signals a shift in the market's immediate perception of the company. As an algorithmic sentiment tracker, BUZZ leverages NLP across social media, blogs, and news to rank stocks by positive-sentiment intensity, meaning a decline in positive public discourse around IBRX would lead to a lower sentiment score. Consequently, the consecutive weight decrease observed in BUZZ from 2.71% on June 10th to 2.57% on June 15th reflects this waning positive sentiment and the associated market price weakness, which will likely translate into a reduced allocation at the upcoming monthly index reconstitution.
weight 2.720% → 2.570% (-0.150 pp)·stock down 12.5% in the 30 days before
Jun 15·entry $7.13·now $7.50
+5.12%
since Jun 15
BUZZ · Weight decrease · 3d
BUZZ, which tracks the BUZZ NextGen AI US Sentiment Leaders Index by applying NLP to social media and news, registered a consecutive weight decrease for ImmunityBio (IBRX) from 2.72% to 2.67% between June 9 and June 12, 2026. This gradual reduction indicates a softening in the positive-sentiment intensity detected by the algorithm for IBRX, a critical signal given the fund's monthly rebalancing cadence for its roughly 75 US large/mid-cap holdings. Such a sentiment shift aligns with IBRX's recent trading, as the stock recorded a 30-day return of -4.0%, suggesting a recent decline that could cool public enthusiasm despite its longer-term gains. As an algorithmic sentiment tracker directly influenced by retail crowd signals, BUZZ's recent adjustments to IBRX’s weighting reflect real-time shifts in broad public perception rather than active fundamental analysis.
weight 2.720% → 2.670% (-0.050 pp)·stock down 12.9% in the 30 days before
Jun 12·entry $7.10·now $7.50
+5.56%
since Jun 12
BUZZ · Accumulation · 5d
ImmunityBio, Inc. (IBRX) currently trades at $7.10, sitting at 61% of its 52-week high after delivering a 165.9% return over the past year and a 20.7% gain in the last 90 days, despite a flat 30-day performance. This specific valuation, off its peak but still significantly up year-over-year, likely spurred renewed or sustained positive discussion across social media, blogs, and news sources, which the VanEck BUZZ NextGen AI US Sentiment Leaders Index monitors via NLP. The algorithmic sentiment tracker, reflecting a retail-crowd signal, identified a continuous build-up of this positive-sentiment intensity for IBRX, leading to its gradual accumulation within the passively managed ETF. This sustained positive sentiment resulted in BUZZ steadily increasing its position, moving from 2.4600% to 2.7200% over the monitoring period in early June, signifying the stock's rising rank within the monthly index reconstitution.
weight 2.460% → 2.700% (+0.240 pp)·stock down 11.3% in the 30 days before
Jun 11·entry $7.20·now $7.50Drifting
+4.10%
since Jun 11
BUZZ · Accumulation · 6d
IBRX's weighting within the BUZZ ETF saw a consistent increase, climbing from 2.45% on June 1st to 2.71% by June 10th, reflecting a measurable uplift in positive sentiment captured by the fund's NLP-driven methodology. As an algorithmic sentiment tracker designed to mirror retail-crowd signals, BUZZ's accumulation suggests heightened positive discussion across social media and other public platforms, even as IBRX trades at $7.20, about 62% of its 52-week high. This gradual accumulation pattern occurs after IBRX delivered a +170.7% 1-year return, indicating that current market discussions might be focusing on its continued momentum or potential given its position significantly below its 52-week peak. The observed pattern of steady buying aligns with BUZZ's passive index rebalancing, where sustained positive sentiment gradually translates into increased portfolio allocation for stocks like IBRX within its ~75 US large/mid cap holdings.
weight 2.450% → 2.710% (+0.260 pp)·stock down 13.9% in the 30 days before
Jun 10·entry $6.98·now $7.50Drifting
+7.38%
since Jun 10
BUZZ · Accumulation · 6d
The gradual accumulation of IBRX in the BUZZ portfolio, from 2.5600% to 2.7200% over nine trading days in early June 2026, reflects a consistent uplift in detected positive sentiment rather than a sudden shift. This steady increase in weight is consistent with BUZZ’s algorithmic strategy, which passively tracks sentiment intensity across social media and news, acting as a barometer for retail-crowd interest that typically builds over time for a Health Care company like ImmunityBio. With IBRX trading at $6.98, at 60% of its 52-week high, and having delivered a 1-year return of +168.5%, this pattern suggests sustained and renewed positive discussion after a period of consolidation, rather than a reactive trade on peak prices or a sharp decline. The ETF’s monthly rebalancing process would incorporate such developing sentiment to adjust holdings, reflecting a growing consensus of optimism even as short-term price movement has been relatively flat. This behavior specifically illustrates how BUZZ identifies a developing positive narrative around a stock that has cooled off from its yearly peak but still retains substantial long-term gains.
weight 2.560% → 2.720% (+0.160 pp)·stock down 14.8% in the 30 days before
Jun 9·entry $7.25·now $7.50Drifting
+3.38%
since Jun 9
+4.53%
since Jun 8
BUZZ · Weight increase · 4d
stock down 17.4% in the 30 days before
Jun 5·entry $6.92·now $7.50Drifting
+8.31%
since Jun 5
+2.81%
since Jun 4
+4.39%
since Jun 3
+3.52%
since Jun 1
-0.33%
since May 29
-2.91%
since May 28
-5.37%
since May 26
-3.17%
since May 21
-6.31%
since May 18
Sell signals show what the stock did after the AI exited. A negative number means the AI's exit was well-timed.